Toll-like receptor 9 (TLR9) (TLR9)

Toll-like receptor 9 (TLR9) is a key pattern recognition receptor that resides in the endosomal membranes of specialized immune cells, such as plasmacytoid dendritic cells and B cells (UniProt P58753). It is specialized to recognize unmethylated cytosine-guanine (CpG) dinucleotide motifs, which are prevalent in microbial DNA but suppressed and methylated in vertebrate DNA, thus acting as a sensor for infectious agents (PubMed: 11069982). Upon ligand binding, TLR9 recruits the adapter protein MyD88, initiating a signaling pathway that activates transcription factors like NF-kappaB and IRF7 to induce the secretion of Type I interferons and pro-inflammatory cytokines (PubMed: 21102464). In the context of cancer, TLR9 agonists are being developed to enhance the immunogenicity of the tumor microenvironment and improve the efficacy of checkpoint inhibitors (PubMed: 32810385). In contrast, the inappropriate recognition of self-DNA by TLR9 is a driver of autoimmune pathologies, such as systemic lupus erythematosus, leading to the development of TLR9 antagonists as potential anti-inflammatory therapies (PubMed: 28839100). Therapeutic agents targeting this pathway include synthetic CpG oligonucleotides used as vaccine adjuvants and small molecule inhibitors designed to treat chronic inflammatory conditions (PubMed: 31512581).

Other names

CD289Toll-like receptor 9 precursorCpG DNA receptor

TLR9 agonists bind to the receptor within endosomes, inducing conformational changes and dimerization that recruit the MyD88 adapter protein. This triggers a signaling cascade involving IRAK kinases and TRAF6, ultimately activating NF-kappaB and IRF7 to drive the expression of pro-inflammatory cytokines and Type I interferons (PubMed: 21102464). Conversely, TLR9 antagonists or inhibitors block the binding of DNA ligands or interfere with the signaling complex to suppress pathological immune activation in autoimmune conditions (PubMed: 28839100).